Biotherapharma_logo.jpg
Biothera Pharmaceuticals Announces Presentation of Clinical Data Supporting Use of a Patient Selection Biomarker for its Phase 2 Cancer Immunotherapy
24 févr. 2017 14h24 HE | Biothera Pharmaceuticals, Inc.
EAGAN, Minn., Feb. 24, 2017 (GLOBE NEWSWIRE) -- Biothera Pharmaceuticals, Inc. will present data today from all cohorts (total N=36) enrolled in a healthy human volunteer study of Imprime PGG, the...
Biotherapharma_logo.jpg
Biothera Pharmaceuticals Initiates Patient Dosing in Phase 2 Trial Investigating Imprime PGG and Merck’s KEYTRUDA® (pembrolizumab)
23 févr. 2017 09h00 HE | Biothera Pharmaceuticals, Inc.
EAGAN, Minn., Feb. 23, 2017 (GLOBE NEWSWIRE) -- Biothera Pharmaceuticals, Inc. today announced that dosing has been initiated in a Phase 2 clinical trial evaluating Biothera’s Imprime PGG in...
Biotherapharma_logo.jpg
Biothera Pharmaceuticals to Discuss Imprime PGG Combination Therapy with Checkpoint Inhibitors at Molecular Medicine Tri-Conference 2017
15 févr. 2017 10h26 HE | Biothera Pharmaceuticals, Inc.
EAGAN, Minn., Feb. 15, 2017 (GLOBE NEWSWIRE) -- Biothera Pharmaceuticals, Inc. today announced that it will deliver two presentations on its Phase 2 candidate Imprime PGG at the 24th annual...
Biotherapharma_logo.jpg
Biothera Pharmaceuticals and Merck Further Expand Research Collaboration to Include Phase 2 Clinical Trial in Head and Neck Cancer
05 déc. 2016 09h30 HE | Biothera Pharmaceuticals, Inc.
EAGAN, Minn., Dec. 05, 2016 (GLOBE NEWSWIRE) -- Biothera Pharmaceuticals, Inc. today announced an expansion of its research collaboration with Merck (known as MSD outside the United States and...